Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessAlbemarle Corporation Further Revised its 2022 Outlook

Albemarle Corporation Further Revised its 2022 Outlook

Add to Favorite
Added to Favorite


Albemarle Corporation (NYSE:ALB) announced further revision for its full 2022-year guidance, which reflects primarily the additional implementation of index-referenced variable-price contracts for battery grade lithium sales. The company now expects Lithium pricing to be up 140% year-over-year, compared to the prior estimate of up 100% year-over-year.
Net sales are now expected to range from $5.8 billion to $6.2 billion, compared to the previous outlook range of $5.2 billion to $5.6 billion and the Street estimate of $5.44 billion. Adjusted EBITDA is now expected in the range of $2.2 – $2.5 billion, compared to the previous outlook of $1.7 – $2.0 billion.
Adjusted diluted EPS is expected in the range of $12.30 – $15.00, compared to the previous outlook of $9.25 – $12.25 and the Street estimate of $10.88.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Advance Auto Parts Downgraded to Sell Amid Earnings Miss and Weak Outlook

CFRA analysts downgraded Advance Auto Parts (NYSE:AAP) from Hold...

Guggenheim Reiterates Buy Rating on Cabaletta Bio Amid Promising Data

Guggenheim analysts reaffirmed a Buy rating and a $23...

Goldman Sachs Initiates Neutral Coverage on Doximity, Highlights Balanced Growth Potential

Goldman Sachs analysts initiated coverage on Doximity (NYSE:DOCS) with...

JPMorgan Downgrades bluebird bio to Underweight Following Q3 Results

JPMorgan analysts downgraded bluebird bio (NASDAQ:BLUE) from Neutral to...